Literature DB >> 12814730

von Hippel-Lindau disease.

Russell R Lonser1, Gladys M Glenn, McClellan Walther, Emily Y Chew, Steven K Libutti, W Marston Linehan, Edward H Oldfield.   

Abstract

von Hippel-Lindau disease is a heritable multisystem cancer syndrome that is associated with a germline mutation of the VHL tumour suppressor gene on the short arm of chromosome 3. This disorder is not rare (about one in 36000 livebirths) and is inherited as a highly penetrant autosomal dominant trait (ie, with a high individual risk of disease). Affected individuals are at risk of developing various benign and malignant tumours of the central nervous system, kidneys, adrenal glands, pancreas, and reproductive adnexal organs. Because of the complexities associated with management of the various types of tumours in this disease, treatment is multidisciplinary. We present an overview of the clinical aspects, management, and treatment options for von Hippel-Lindau disease.

Entities:  

Mesh:

Year:  2003        PMID: 12814730     DOI: 10.1016/S0140-6736(03)13643-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  399 in total

1.  First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.

Authors:  Anna Roma; Marco Maruzzo; Umberto Basso; Antonella Brunello; Rita Zamarchi; Elisabetta Bezzon; Fabio Pomerri; Stefania Zovato; Giuseppe Opocher; Vittorina Zagonel
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

2.  Long-term stability after multilevel cervical laminectomy for spinal cord tumor resection in von Hippel-Lindau disease.

Authors:  Ashok R Asthagiri; Gautam U Mehta; John A Butman; Martin Baggenstos; Edward H Oldfield; Russell R Lonser
Journal:  J Neurosurg Spine       Date:  2011-01-28

Review 3.  Renal cancer: oxygen meets metabolism.

Authors:  Volker H Haase
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

Review 4.  Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.

Authors:  Roeland F de Wilde; Barish H Edil; Ralph H Hruban; Anirban Maitra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

5.  Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma.

Authors:  C Lance Cowey; W Kimryn Rathmell
Journal:  Expert Opin Drug Discov       Date:  2008-03       Impact factor: 6.098

6.  Supratentorial hemangioblastoma: clinical features, prognosis, and predictive value of location for von Hippel-Lindau disease.

Authors:  Steven A Mills; Michael C Oh; Martin J Rutkowski; Michael E Sughrue; Igor J Barani; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-06-21       Impact factor: 12.300

Review 7.  Recent advances in intradural spinal tumors.

Authors:  Muhammad M Abd-El-Barr; Kevin T Huang; Ziev B Moses; J Bryan Iorgulescu; John H Chi
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

8.  Biliary and gastric drainage in advanced pancreatic serous cystadenoma and portal hypertension in Von Hippel-Lindau syndrome.

Authors:  Daniel C Medina; Ricardo Osorno; Cherif N Boutros
Journal:  J Gastrointest Oncol       Date:  2014-04

Review 9.  MicroRNAs in the pathogenesis of cystic kidney disease.

Authors:  Yu Leng Phua; Jacqueline Ho
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

10.  Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease.

Authors:  Xiaoling Liang; Defen Shen; Yongsheng Huang; Chunyue Yin; Christine M Bojanowski; Zhengping Zhuang; Chi-Chao Chan
Journal:  Ophthalmology       Date:  2006-10-27       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.